<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168077">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01790399</url>
  </required_header>
  <id_info>
    <org_study_id>SENTIMAG-1213</org_study_id>
    <nct_id>NCT01790399</nct_id>
  </id_info>
  <brief_title>IDENTIFICATION OF SENTINEL NODE(S) IN BREAST CANCER</brief_title>
  <acronym>SENTIMAG</acronym>
  <official_title>IDENTIFICATION OF SENTINEL NODE(S) BY SENTIMAG® /SIENNA+ IN BREAST CANCER: FEASIBILITY STUDY</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sysmex America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is based on the identification of sentinel node(s) by SENTIMAG / SIENNA + in
      addition to the usual method (blue and /or radioactive product). This is a feasibility study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Identification of Sentinel node(s)

             1. Step 1: Identification using the technique Nanocis Sub-areolar injection of
                Tc99m-Nanocis ® the day before or the day of surgery

             2. Step 2: Identification using the technique SentiMag ® / Sienna+ Injection Sienna +
                ™ should be done just after induction of anesthesia and before the injection of
                Patent Blue dye

             3. Step 3: Identification using the technique of Patent Blue Dye or Lymphotropic dye
                injection or Patent Blue is performed after induction of anesthesia, the injection
                and production Sienna + ™, the operating theater by the surgeon

        -  Detection of Sentinel node(s)

             1. Step 1: probe SentiMag ® (study)

             2. Step 2: hand probe gamma radiation detection and / or colorimetric detection
                (standard)

        -  Sentinel node's excision of radioactive and / or blue and / or magnetic (colored
           brown-brown)

        -  After the procedure:

      Characterization of the size and weight of lymph nodes, histological and / or molecular OSNA
      and linking nodal status with the detection rate of sentinel nodes for each technique.

      NB: In case of synchronous bilateral cancer, 2 records are possible
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Sentinel node(s)detected with new technical</measure>
    <time_frame>The day of surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Idenfication 's rate of sentinel  nodes detected with new technical(SentiMag ® / Sienna + TM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detected node(s) for each method(standard and new)</measure>
    <time_frame>The day of surgery</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Proportion of detected nodes for each method(standard and new)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">115</enrollment>
  <condition>BREAST CANCER</condition>
  <arm_group>
    <arm_group_label>Identification of sentinel node(s)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Excision of sentinel node(s)</intervention_name>
    <description>Excision of sentinel node(s) using SENTIMAG / SIENNA + in addition to the usual method (blue and /or radioactive product)</description>
    <arm_group_label>Identification of sentinel node(s)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with invasive breast cancer or microinfiltrant proven by cytology and
             histo-or whatever the histological type

          -  cT0/cT1/cT2 (up to 5 cm) CN0 clinical and / or ultrasound and without prior treatment
             (chemotherapy or neoadjuvant hormone )

          -  Age greater than or equal to 18

          -  Reporting of breast surgery and axillary staging of sentinel lymph node

          -  Using effective contraception (BHCG negative)

          -  Patient affiliated with a health insurance

          -  Consent signed by the patient

        Exclusion Criteria:

          -  T3 or T4 tumors (&gt; 5 cm, cutaneous or muscle inflammation or cancer)

          -  Presence of a clinically suspicious axillary adenopathy or imaging

          -  Tumors bifocal or multifocal known before Surgery

          -  History of breast surgery or axillary

          -  Patient metastatic

          -  Patient with a cons-indication anesthesia and / or surgery

          -  Intolerance or hypersensitivity to the compounds or iron dextran or superparamagnetic
             iron oxide or to Patent blue dye in centers where it is commonly used

          -  Patient can not receive a radioactive isotope to the sentinel lymph node  resection

          -  Allergy radioactive product

          -  Chronic iron overload

          -  Pacemaker or other implantable device in the chest wall

          -  Failure to submit to medical study for geographical, social or psychological

          -  Patient deprived of liberty or under guardianship

          -  Pregnant or lactating
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Louis MD HOUPEAU</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31 052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre les nancy</city>
        <zip>54 511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>March 5, 2014</lastchanged_date>
  <firstreceived_date>February 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SENTINEL NODE</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
